\
&
Contact us
\
&
Contact us
This was 1 year ago
LocationBrussels
The use of synthetic data has emerged as an interesting technique to respond to the increasing demands for data to fuel data analytics and AI, especially in cases where sensitive information is involved.
This event, organised by the European Commission, will showcase the potential of synthetic data and explore potential limitations in ensuring full information privacy.
The panellists during this conference will discuss the role that synthetic data can play in the digital economy, strategies to promote its use and the associated risks.
For more information on the agenda and to register, please visit the event website. Please note that due to the limited capacity of the venue, registrations are subject to validation by the organisers.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Security Digital, Industry & Space Digital Europe Cybersecurity Defence
Research Infrastructures Culture and society Climate, Energy, Mobility
Digital, Industry & Space AI Continent Deployment: Best use of technologies
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
